Biolinq: Less pain, $58m gain for tiny glucose sensor

Written by

Anette Boyle

In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA. The round brings the total raised to more than $170 million. With good response so far, the company is optimistic that it can attract more funding in short order. “Biolinq also plans to raise a series C financing of more than $100 million to support commercialization at the end of this year,” Biolinq CEO Rich Yang told BioWorld.

Full article here: https://www.bioworld.com/articles/706919-biolinq-less-pain-58m-gain-for-tiny-glucose-sensor?v=preview

Other news

Mass Device

June 2, 2024

Biolinq raises $58M to support intradermal glucose sensor

Biolinq announced today that it completed $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated.

Written by

Sean Whooley

Medical Device Network

June 2, 2024

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq is eying an FDA application this year, according to CEO Richard Yang. “The pivotal study started in March 2024 and we plan to file for US Food and Drug Administration (FDA) clearance this year.” said Yang.

Biolinq lands $58m to advance wearable metabolic health technology

Health tech company Biolinq has secured $58 million in new funding to advance its biosensor technology for enhancing metabolic health. Company targets clinical trial of groundbreaking CGM device that detects blood glucose levels just below the surface of the skin.

Written by

Danny Sullivan